In a patient with advanced HCC who experienced progression on durvalumab plus tremelimumab, nivolumab plus ipilimumab achieved a clinically meaningful response despite renal comorbidity that limited VEGF‐targeted options. Here, VEGFA is linked to hepatocellular carcinoma.